Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Impel Neuropharma is raising $5,622,139.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Adrian Adams played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Impel Neuropharma

Impel NeuroPharma, Inc. is a private Seattle based company developing intranasal drug treatments for central nervous system (CNS) disorders. We have developed a novel drug delivery platform, the POD technology, that administers medicine deep into the nasal cavity. The POD technology achieves consistent and predictable biodistribution of the medicine to improve clinical outcomes for patients. We want to develop the next generation of therapeutics for central nervous system (CNS) disorders. We believe that intranasal delivery is a vastly underutilized route of drug administration that holds great promise in addressing unmet needs for patients managing CNS disorders. We strive daily to utilize our knowledge and technology to deliver better outcomes for patients.

To learn more about Impel Neuropharma, visit http://impelnp.com/

Contact:
Adrian Adams, President and Chief Executive Officer
206-568-1466
aadams@impelnp.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved